Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Sparing Outcomes, Non-Opioid Alternatives To Get Spotlight From US FDA Advisory Cmte.

Executive Summary

The advisory committee will discuss a broad range of questions on a facet of FDA's opioid strategy that has received less attention than the others.

You may also be interested in...



Pain/Addiction Products Need Regulatory Streamlining To Incentivize Development, Sponsors Say

Industry speakers offer series of suggestions for ways to incentivize development of pain and addiction products at US FDA public meeting on the opioid crisis.

US FDA Faced With Suite Of Opinions Defining 'Clinically Meaningful' Opioid-Sparing Claims

Advisory committee agreed that statistically significant reduction in average opioid use and decrease in absolute amount were insufficient components on their own; a decrease in duration of use and a decrease in the amount of patients who don't need opioids received some support.

Opioid Prescribing Guidelines Put US FDA In Unfamiliar Territory

FDA has always described its role as stopping short of regulating the practice of medicine. When it comes to opioids, that is no longer the case. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel